{"id":20112,"date":"2023-09-13T11:39:47","date_gmt":"2023-09-13T11:39:47","guid":{"rendered":"https:\/\/clinlabint.com\/?p=20112"},"modified":"2023-09-13T11:39:47","modified_gmt":"2023-09-13T11:39:47","slug":"global-access-diagnostics-reintroduces-it-leish-test-for-visceral-leishmaniasis","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/global-access-diagnostics-reintroduces-it-leish-test-for-visceral-leishmaniasis\/","title":{"rendered":"Global Access Diagnostics reintroduces IT-Leish test for visceral leishmaniasis"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Global Access Diagnostics reintroduces IT-Leish test for visceral leishmaniasis<\/h1>\/ in Product News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Global Access Diagnostics (GADx), a social enterprise prioritising equitable access to diagnostics, has introduced IT-Leish, a rapid diagnostic test (RDT) for visceral leishmaniasis (VL). The company acquired the manufacturing rights for IT-Leish from Bio-Rad in September 2022 to prevent its withdrawal from the market\u00a0and has since ensured the regulatory requirements have been met for reintroduction to the market.\u00a0<\/strong><\/p>\n

<\/p>\n

IT-Leish is a high-performance, immuno-chromatographic RDT that is used for the diagnosis of VL, a life-threatening neglected tropical disease (NTD) transmitted by phlebotomine sandflies. Early VL diagnosis is a vital component of controlling the disease, which is considered fatal if not treated rapidly. IT-Leish is a trusted RDT, taking 20 minutes to generate results. It provides reliable and accurate confirmation of clinically suspected cases of VL to enable early diagnosis, reducing disease fatality.<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

In January 2023, the WHO announced the development of a strategic plan to review the current epidemiological situation in East Africa, with regional and country-level elimination targets for 2023-2027. As part of this and the WHO\u2019s wider 2021-2030 road map for NTDs, plans will be drawn to ensure long-term and sustainable financing and the procurement of medical supplies, including first-line diagnostics. By harnessing its expertise in lateral flow development and manufacturing, GADx has ensured IT-Leish is fit for regulatory purposes and available on the market as UKCA marked to support these critical campaigns.<\/p>\n

For more information visit: www.globalaccessdx.com<\/a>
\nDigital issue: Please click here<\/a> for more information<\/p>\n<\/div><\/section>
\n

\n